Claritin, Hismanal are formulary choices in MAMSI patient switch letter funded by Schering.
SCHERING-FUNDED MAMSI SWITCH LETTERS SUGGEST CLARITIN OR HISMANAL to replace either Hoechst Marion Roussel's Seldane or Pfizer's Zyrtec prescription antihistamines. Letters to patients mailed in mid-June suggest: "At your next office visit or before you obtain your next refill, why not ask your physician about Claritin, Hismanal or Claritin-D." Rockville, Md.-based Mid-Atlantic Medical Services, Inc. also sent letters to providers noting that Schering-Plough's Claritin and J&J's Hismanal are lower-cost alternatives for the health plan.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth